



Mikael Dolsten, M.D., Ph.D.
President, Worldwide Research and Development, Pfizer Inc.



Mikael Dolsten, M.D., Ph.D. is President of Pfizer Worldwide Research and Development (WRD) and Executive Vice President of Pfizer Inc. He is focused on advancing the company's pipeline and provides scientific leadership for all Pfizer products. Dr. Dolsten is a member of the Pfizer Executive Leadership Team and co-chairs the company's Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Dr. Dolsten leads the WRD group at Pfizer, comprised of approximately 9000 R&D colleagues worldwide supporting Pfizer's R&D projects and marketed products. He is responsible for all research at Pfizer, including development of compounds through proof of concept (POC) and provides safety, regulatory and clinical operations activities to all of Pfizer's projects and marketed products. WRD is comprised of Pfizer's research units and Pfizer's partner lines. The research units include Cardiovascular and Metabolic/Renal Disease; Neuroscience and Pain; Oncology; Inflammation and Immunology; Vaccines; and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit, Rinat. Mikael leads Pfizer's partner line groups that oversee safety, regulatory, development operations, external R&D innovation, as well as science-based teams in biosimilars R&D, pharmaceutical sciences, drug safety R&D and design of small, large and vaccines therapies.

Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research responsible for global research and development activities. Before joining Wyeth, he served as Executive Vice President for Worldwide Research at Boehringer Ingelheim. His earlier career as a research leader included VP leadership positions with AstraZeneca, Pharmacia and Upjohn. Mikael has, during his 25 years in the Pharmaceutical industry, led R&D groups that have selected more than 100 Candidate drugs for treatment of human disease and supported the R&D advancement of some 20 important novel medicines and vaccines. Dr. Dolsten has also served as a Private Equity partner at Orbimed, the world's largest healthcare focused investment company. In addition, he gained leadership experience from five large-scale M&A transactions.

Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden. Mikael is a governor of the New York Academy of Sciences, a member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), co-lead for the industry-NIH Accelerating Medicine Partnership (AMP) Executive Committee and serves on the PhRMA Foundation Board of Directors. He has been a board member of a Swedish Business School for Innovation and Chamber of Commerce. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.